A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
A study for adult patients with recurrent glioblastoma multiforme using study drug SL-701
Sponsor: Stemline Therapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAN8010
U.S. Govt. ID: NCT02078648
Contact: Fabio Iwamoto: 212-342-0571 / fi2146@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if SL-701 is safe and tolerable for patients with recurrent glioblastoma multiforme (GBM). The study will also look at what effect SL-701 has on patient's brain tumor. SL-701 is a type of anti-cancer vaccine made up of parts 3 different short proteins called "peptides" which are frequently found on this type of brain tumor. The vaccine is intended to activate the immune system to recognize and kill the brain tumor cells that have the same protein.
This study is closed
Fabio Iwamoto, MD
Do You Qualify?
Do you have a confirmed diagnosis of GBM? Yes No
Have you had prior cancer chemotherapy or an investigational agent for recurrent/progressive GBM as part of initial therapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Fabio Iwamoto